- Home
- YCBD vs ENLV Comparison
YCBD vs ENLV Comparison
Compare YCBD & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YCBD | ENLV |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0M | 5.1M |
| IPO Year | 2018 | 2014 |
Fundamental Metrics
Financial Performance| Metric | YCBD | ENLV |
|---|---|---|
| Price | $0.37 | $0.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 87.1K | ★ 1.7M |
| Earning Date | 08-13-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,190,468.00 | N/A |
| Revenue This Year | $14.24 | N/A |
| Revenue Next Year | $30.43 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.33 | $0.19 |
| 52 Week High | $2.56 | $7.64 |
Technical Indicators
Market Signals| Indicator | YCBD | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 39.03 | 18.86 |
| Support Level | $0.33 | N/A |
| Resistance Level | $0.53 | $1.26 |
| Average True Range (ATR) | 0.03 | 0.04 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 35.14 | 2.48 |
Price Performance
Historical ComparisonAbout YCBD cbdMD Inc.
cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.